title: Effect of CYP1A2 deficiency on heterocyclic amine DNA adduct levels in mice.
abstract: The contribution of CYP1A2 to the formation of DNA adducts of the cooked meat-derived heterocyclic amines (HCAs) 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) was examined in CYP1A2-null (knock-out, KO) and wild-type (WT) mice. IQ (25 mg and 75 mg/kg) and PhIP (150 mg/kg) were administered by gavage to mice and DNA adduct levels in liver, kidney, mammary gland and colon were examined by the 32P-postlabeling assay. Three hours after either dose of IQ, adducts levels in liver and kidney of KO mice were 20-30% of the levels in WT mice, a difference that was statistically significant (Student's t-test, P < 0.05). In the colon, adduct levels in KO mice were significantly lower than in the WT mice only at the lowest dose of IQ (1.6+/-0.6 vs 4.6+/-0.7, respectively, relative adduct labeling (RAL) x 10(8), mean+/-S.E.M., n = 3-5 mice). In the mammary gland, however, there was no difference in IQ-DNA adduct levels in KO and WT mice at either dose of IQ. Three hours after dosing with PhIP, PhIP-DNA adduct levels were statistically significantly lower in KO mice than in WT mice in all tissues examined. PhIP-DNA adducts in liver and kidney of WT mice were 9.9+/-1.1 and 22.5+/-6.9, respectively, whereas no PhIP-DNA adducts were detected in either organ of KO mice (limit of detection, 1.4-2.8 x 10(9)). PhIP-DNA adduct levels in mammary gland and colon of WT mice were 47.1+/-9.5 and 58.0+/-21.7, respectively, but accordingly only 3.8+/-0.7 and 5.4+/-0.9 in KO mice. The findings indicate that CYP1A2, responsible for IQ and PhIP N-hydroxylation, the first step in the metabolic action, significantly effects DNA adduct formation in vivo. However, the data raise the possibility that other cytochromes P450 as well as other pathways of activation potentially contribute to DNA adduct formation in specific organs, depending on the HCA substrate.
authors.affiliation: Department of Veterinary Medicine, King Saud University, Buraydah, Saudi Arabia. elizabeth_snyderwine@nih.gov
authors.forename: E G
authors.initials: EG
authors.lastname: Snyderwine
authors.forename: M
authors.initials: M
authors.lastname: Yu
authors.forename: H A J
authors.initials: HA
authors.lastname: Schut
authors.forename: L
authors.initials: L
authors.lastname: Knight-Jones
authors.forename: S
authors.initials: S
authors.lastname: Kimura
mesh_terms: D000588:Amines / Q000378:metabolism*; D000818:Animals; D003106:Colon / Q000378:metabolism; D019388:Cytochrome P-450 CYP1A2 / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D018736:DNA Adducts / Q000378:metabolism*; D005260:Female; D006571:Heterocyclic Compounds / Q000378:metabolism*; D007093:Imidazoles / Q000008:administration & dosage / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008321:Mammary Glands, Animal / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011804:Quinolines / Q000008:administration & dosage / Q000378:metabolism
chemical_list: D000588:Amines; D018736:DNA Adducts; D006571:Heterocyclic Compounds; D007093:Imidazoles; D011804:Quinolines; C029216:2-amino-3-methylimidazo(4,5-f)quinoline; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; D019388:Cytochrome P-450 CYP1A2